Rick Watson, MD
Pulmonary Disease · Findlay, OHNPI 1649228537
Payments from drug & device makers
Across 45 payments — averaging $23.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$223
- GSK$128
- ARS Pharmaceuticals Operations, Inc.$103
- Dexcom, Inc.$95
- Regeneron Healthcare Solutions, Inc.$67
- Novo Nordisk$63
- plus $372 from 17 others
What the payments were for
- Food & beverage$1,049100%
- Education$30%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 11 | $223 |
| GSK | 5 | $128 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $103 |
| Dexcom, Inc. | 1 | $95 |
| Regeneron Healthcare Solutions, Inc. | 3 | $67 |
| Novo Nordisk | 3 | $63 |
| Boehringer Ingelheim | 2 | $61 |
| Corcept Therapeutics | 3 | $48 |
| E.r. Squibb & Sons, L.L.C. | 1 | $38 |
| Sanofi | 2 | $31 |
| Verona Pharma, Inc. | 1 | $23 |
| Inogen, Inc. | 1 | $22 |
| Amgen | 1 | $19 |
| Phathom Pharmaceuticals, Inc. | 1 | $17 |
| Daiichi Sankyo Inc. | 1 | $16 |
| Lilly USA, LLC | 1 | $15 |
| Tandem Diabetes Care, Inc. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| AbbVie | 1 | $13 |
| Pfizer | 1 | $13 |
| Shire North American Group Inc | 1 | $12 |
| Johnson & Johnson | 1 | $12 |
| United Therapeutics Corporation | 1 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NEFFY$103
How this compares
$1,052 in reported general payments places this provider in the 40th percentile of 571 pulmonary disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 286 | $261,650 |
| OfevNintedanib Esylate | 14 | $119,896 |
| Spiriva RespimatTiotropium Bromide | 130 | $94,704 |
| Breo ElliptaFluticasone/Vilanterol | 150 | $85,447 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 108 | $55,153 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 44 | $40,817 |
| Pirfenidone | 22 | $38,074 |
| SymbicortBudesonide/Formoterol Fumarate | 121 | $37,980 |
| Spiriva HandihalerTiotropium Bromide | 50 | $35,426 |
| Arnuity ElliptaFluticasone Furoate | 76 | $26,927 |
| Advair HfaFluticasone Propion/Salmeterol | 36 | $24,587 |
| DuleraMometasone/Formoterol | 43 | $21,658 |
| Incruse ElliptaUmeclidinium Bromide | 32 | $19,697 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 133 | $18,588 |
| Qvar RedihalerBeclomethasone Dipropionate | 46 | $17,469 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta, Incruse Ellipta | $128 | $448,874652 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $61 | $231,687172 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $223 | $86,867184 claims |
| PfizerEliquis | $13 | $6,43111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 571 pulmonary disease providers in Ohio.
Other pulmonary disease in Findlay
- Bruce CorserCincinnati$8.2M
- Edward CordascoColumbus$8M
- Kristin HighlandCleveland$3.2M
- Brian ZenoColumbus$2.9M
- Jean ElwingCincinnati$2.4M
- Roy St JohnColumbus$1.9M
- Nishant GuptaCincinnati$1.5M
- Robert BaughmanCincinnati$1.1M
- Francis McCormackCincinnati$1.1M
- Leslie TolleCleveland$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.